Equillium, Inc. (EQ) stock
Close on Nov 11, 2026Market cap $90.04MP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $90.04M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 1.61
- Dividend yield
- –
- Free cash flow yield
- -22.31%
Fundamentals
- Net income
- -$18.01M
- EPS, diluted
- -$0.39
- Free cash flow
- -$20.09M
- Book value per share
- $0.50
- Diluted shares
- 112M
Trading
- Next earnings
- Nov 12, 2026 (estimated, after the close)
- Previous close
- $1.46
- Open
- $1.47
- Day's range
- $1.41 – $1.50
- Volume
- 215,160
- Average volume (20 days)
- 461,015
- Beta (5 years)
- 0.45
- 52-week range
- $0.76 – $3.54
- RSI (14 days)
- 47.6
- Volatility (1 year)
- 103.6%
- Relative volume
- 0.37×
- WACC
- 7.4%
Market cap history
Month-end market cap since 2018, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | EQ | S&P 500 | Difference | EQ per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +0.7% | -2.4% | +3.1 pts | ||
| 3 months | -36.3% | -1.2% | −35.2 pts | ||
| Year to date | -8.4% | +12.3% | −20.7 pts | ||
| 1 year | +46.2% | +12.4% | +33.8 pts | ||
| 3 years | +186.5% | +78.8% | +107.7 pts | +42.0% | +21.4% |
| 5 years | -75.0% | +75.2% | −150.1 pts | -24.2% | +11.9% |
| 10 years | -96.6% | +311.1% | −407.7 pts | -28.7% | +15.2% |
Nine years at a glance
Fiscal years 2017 to 2025 and trailing twelve months, USD
Revenue
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Equillium filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- Results
- Results
- Results
About Equillium
Pharmaceutical Preparations
Equillium, Inc. is a biotechnology company focused on developing novel therapeutics for severe autoimmune and inflammatory disorders. Its pipeline includes EQ504, an aryl hydrocarbon receptor modulator being developed for the treatment of ulcerative colitis and other gastrointestinal conditions, with potential expansion into inflammatory lung diseases. The company is also evaluating EQ302, an orally administered bi-specific inhibitor of IL-15 and IL-21 designed to address gastrointestinal disorders such as celiac disease. Equillium focuses on addressing unmet medical needs across gastroenterology, dermatology, and pulmonology.
Company profile, executives and historyEquillium stock: common questions
What is Equillium's stock price?
EQ closed at $1.42 on Nov 11, 2026, down 2.41% on the day. Over the past 52 weeks it traded between $0.76 and $3.54.
What is Equillium's market cap?
Equillium was worth $90.04M at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is EQ's P/E ratio?
Equillium lost money over fiscal 2025 (diluted EPS -$0.39), so it has no meaningful P/E ratio.
Does Equillium pay a dividend?
No. Equillium has not paid a cash dividend over the last twelve months.
When does Equillium report earnings next?
Equillium is expected to report Q3 FY2026 results on Nov 12, 2026, after the close. The date is estimated from its past reporting pattern until the company confirms it.
How has EQ stock performed over the past year?
Including dividends, EQ returned +46.2% over the past year, against +12.4% for the S&P 500.
How many EQ shares are sold short?
6M shares were sold short at the latest FINRA report, 10.12% of the float, or 9.5 days of average trading volume.
Who are Equillium's competitors?
Companies most similar to Equillium by business, industry and size include NKTR, QTTB, EVMN, CUE, VTVT.
See a number that looks wrong?